drugset
drugset / Trial / NCT03779113

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

NCT03779113 ↗

Phase 1 Terminated 69 enrolled Hutchmed
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

Timeline

Start
2019-09-26
Primary completion
2025-02-26
Completion
2025-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Sovleplenib Small molecule 100 mg Oral
Subject Sovleplenib Small molecule 200 mg Oral
Subject Sovleplenib Small molecule 400 mg Oral
Subject Sovleplenib Small molecule 600 mg Oral
Subject Sovleplenib Small molecule 800 mg Oral

Indications

non-Hodgkin lymphoma